Send to

Choose Destination
Am J Transplant. 2018 Dec 27. doi: 10.1111/ajt.15239. [Epub ahead of print]

Optimal Timing of Hepatitis C Treatment among HIV/HCV Co-infected ESRD Patients: Pre vs. Post-Transplant.

Author information

University of Alabama at Birmingham Comprehensive Transplant Institute, Birmingham, AL, USA.
University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Boston University School of Medicine, Boston, MA, USA.


End-stage renal disease (ESRD) patients co-infected with HCV and HIV have access to effective treatment options for HCV infection. However, they also have access to HCV-infected kidneys, which historically afford shorter times to transplantation. Given high waitlist mortality and rapid progression of liver fibrosis among co-infected kidney-only transplant candidates identifying the optimal treatment strategy is paramount. Two strategies, treatment pre- and post-transplant, were compared using Monte Carlo microsimulation of 1,000,000 candidates. The microsimulation was stratified by liver fibrosis stage at waitlist addition and wait-time over a lifetime time horizon. Treatment post-transplant was consistently cost-saving as compared to treatment pre-transplant due to the high cost of dialysis. Among patients with low fibrosis disease (F0-F1), treatment post-transplant also yielded higher life months (LM) and quality-adjusted life months (QALM) except among F1 candidates with wait-times >18 months. For candidates with advanced liver disease (F2-F4), treatment pre-transplant afforded more LM and QALM unless wait-time was < 18 months. Moreover, treatment pre-transplant was cost-effective for F2 candidates with wait-times > 71 months and F3 candidates with wait-times > 18 months. Thus, optimal timing of HCV treatment differs based on liver disease severity and wait-time, favoring pre-transplant treatment when cirrhosis development prior to transplant seems likely. This article is protected by copyright. All rights reserved.


Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center